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Abstract
Duchenne muscular dystrophy (DMD) is a debilitating fatal X-
linked muscle disorder. Recent findings indicate that IGFs play a
central role in skeletal muscle regeneration and development.
Among IGFs, insulinlike growth factor 2 (IGF2) is a key regulator of
cell growth, survival, migration and differentiation. The type 2 IGF
receptor (IGF2R) modulates circulating and tissue levels of IGF2 by
targeting it to lysosomes for degradation. We found that IGF2R
and the store-operated Ca2+ channel CD20 share a common
hydrophobic binding motif that stabilizes their association. Silenc-
ing CD20 decreased myoblast differentiation, whereas blockade of
IGF2R increased proliferation and differentiation in myoblasts via
the calmodulin/calcineurin/NFAT pathway. Remarkably, anti-IGF2R
induced CD20 phosphorylation, leading to the activation of
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) and
removal of intracellular Ca2+. Interestingly, we found that IGF2R
expression was increased in dystrophic skeletal muscle of human
DMD patients and mdx mice. Blockade of IGF2R by neutralizing
antibodies stimulated muscle regeneration, induced force recovery
and normalized capillary architecture in dystrophic mdx mice
representing an encouraging starting point for the development of
new biological therapies for DMD.
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Introduction
Duchenne muscular dystrophy (DMD) is a devastating X-linked
disease characterized by progressive muscle weakness and caused
by a lack of dystrophin protein in the sarcolemma of muscle fibres
(Emery, 2002). Impaired muscle regeneration with exhaustion of the
satellite cell pool is a major hallmark of DMD. Members of the
insulin-like growth factor (IGF) family are secreted during muscle
repair and promote muscle regeneration and hypertrophy. Among
the IGFs, IGF1 signalling has been extensively characterized for its
capacity to promote the proliferation and differentiation of satellite
cells, regulate muscle hypertrophy and ameliorate the features of
muscular dystrophy (Florini et al, 1996; Barton et al, 2002; Zanou &
Gailly, 2013). Nevertheless, little is known about the role of IGF2 in
skeletal muscle development and regeneration in vivo. In vitro stud-
ies have shown that the IGF2 protein plays a role in a later step of
myoblast differentiation (Florini et al, 1991; Wilson et al, 2003; Ge
et al, 2011). Interestingly, it was previously shown that there is a
link between the Myod and Igf2 genes in myoblast cell culture (Mon-
tarras et al, 2005). Further studies suggested that IGF2, by binding
to the IGF1 receptor, activates the Akt pathway and downstream
targets of Myod, although the exact mechanisms underlying these
processes have not been identified (Wilson & Rotwein, 2006, 2007).
IGF2 signalling is regulated by IGF-binding proteins, which
sequester circulating IGF2; the IGF2 receptor (IGF2R), which
reduces IGF2 bioactivity (Brown et al, 2009); and the insulin recep-
tor and IGF1 receptor, both of which can be activated by IGF2
(Livingstone, 2013). The extracytoplasmic region of IGF2R has three
binding sites: one for IGF2 in domain 11 and two for Man-6-P in
domains 3, 5 and 9 (Dahms et al, 1993; Reddy et al, 2004; Williams
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et al, 2007). Binding between IGF2 and IGF2R induces the lysoso-
mal degradation of IGF2. Hence, IGF2R serves to clear IGF2 from
the circulation or degrade excess circulating IGF2 (Fargeas et al,
2003; Spicer & Aad, 2007). Soluble IGF2R can affect the size of
some organs exclusively by reducing the biological activity of IGF2
(Zaina & Squire, 1998).
Here, we report that IGF2R and the store-operated Ca2+ channel
CD20 share a common hydrophobic binding motif that stabilizes
their association. Intracellular Ca2+ regulation is compromised in
dystrophic muscle fibres. Mechanisms that affect the influx of Ca2+
into dystrophic muscle fibres include membrane tears (Turner et al,
1988; Straub et al, 1997; Blake et al, 2002), stretch-activated chan-
nels (Gervasio et al, 2008), Ca2+ leak channels (Fong et al, 1990)
and leaky Ca2+ release channels (Bellinger et al, 2009); it has also
been speculated that the function of SERCA, the main protein
responsible for Ca2+ reuptake into the sarcoplasmic reticulum (SR),
is compromised in mdx mice (Tutdibi et al, 1999; Nicolas-Metral
et al, 2001).
We found that IGF2R targeting regulated the phosphorylation of
CD20 and thereby induced SERCA activation in myoblasts. Interest-
ingly, a delay in muscle differentiation was observed in CD20-
silenced (shCD20) myoblasts, whereas the expression levels of early
and late differentiation markers were increased after blockade of
IGF2R. These features were accompanied by the activation of the
calmodulin/calcineurin/NFAT pathway, suggesting that an IGF
post-translational modulatory mechanism regulates muscle differen-
tiation. Notably, IGF2R expression was increased in the dystrophic
muscle tissues of mdx mice, while the phosphorylation of IGF2R
was significantly decreased. Because IGF2R and CD20 interactions
could affect dystrophic muscle tissues, we hypothesized that IGF
clearance was faster and its bioavailability lower in dystrophic
muscles than in normal muscles and that these changes were
accompanied by perturbation of Ca2+ reuptake into the SR. Remark-
ably, in mdx mice, blockade of IGF2R increased muscle regeneration
and significantly recovered muscle force via SERCA activation and
Ca2+ reuptake. The IGF2 pathway affects vascular architecture, and
the vessel structures of dystrophic skeletal muscles were clearly
disorganized in mdx mice; hence, we examined the effect of anti-
IGF2R antibodies on blood vessels in the skeletal muscles of mdx
mice and found that muscle capillaries were linearized and exhib-
ited normal architecture and maturation. Overall, these data demon-
strated that a biological therapy targeting IGF2R leads to
improvement of muscle regeneration and suppression of the patho-
logical cascade associated with muscle dystrophic events.
Results
CD20 phosphorylation is affected by IGF-driven pathway
Given the finding that CD20 acts as a mediator/modulator of store-
operated calcium entry (SOCE) in skeletal myoblasts (Parolini et al,
2012), we were prompted to evaluate the functional impact of CD20
in C2C12 myoblast differentiation and analyse its possible interac-
tions with the IGF pathway. IGF1 and IGF1R expression were not
increased in 10 nM IGF1-treated C2C12 myoblasts (Fig 1A), but
IGF1 treatment did induce a significant increase in transcription-
dependent IGF2 production (Fig 1A). Immunofluorescence staining
revealed that treating C2C12 cells with 10 nM IGF1 increased IGF2
production (Fig 1B). Moreover, over-expressing CD20 in C2C12 cells
also resulted in a transcriptional increase in IGF2 expression
(Fig 1A). In contrast, IGF2 expression was not detected in untreated
C2C12 cells (Fig 1A and B) or CD20 shRNA-transfected C2C12 cells
(Fig 1A). To assess the effect of stable CD20 inhibition, C2C12 cells
were exposed to lentiviral particles designed to deliver constructs
encoding shRNAs that targeted the CD20 mRNA. Knockdown effi-
ciency was assayed after infected cells were selected by WB analy-
sis, which revealed that CD20 protein expression was 60% silenced
(Fig EV1A). To assess whether CD20 phosphorylation is affected by
an IGF1-driven pathway, C2C12 myoblasts were exposed to 1 nM or
10 nM IGF1 for 2 h or overnight. The impact on CD20 phosphoryla-
tion was then detected by specific phosphor-Ser and phosphor-Thr
antibodies. After 2 h of exposure to 10 nM IGF1, the level of phos-
phorylation of CD20 was significantly increased at both Ser and Thr
residues (Fig 1C). CD20 serine phosphorylation was also increased
after overnight exposure to 1 nM and 10 nM IGF1, although to a
lesser extent (Fig 1C). Blockade of IGF2R induced a significant
higher level of CD20 phosphorylation than was observed in IGF1-,
shCD20- and anti-Flag-treated myoblasts (Fig 1D). Interestingly,
CD20 serine phosphorylation was significantly increased in
myoblasts co-stimulated with either 10 or 100 nM of IGF2 (Fig 1E).
Together, these findings indicate that the activation of CD20-related
signalling can be induced by IGFs in skeletal myoblasts. Moreover,
IGF2R expression and phosphorylation were reduced in shCD20-
and anti-IGF2R-treated myoblasts (Fig 1F). Treatment with anti-
IGF2R increased IGF2R-Gai2 interactions and regulated IGF1R phos-
phorylation, suggesting a shift in IGF1-IGF1R interactions (Fig 1G
and H).
IGF2R binding to CD20 is relevant for myogenic differentiation
We next sought to verify whether there are interactions between
IGF2R and CD20. Automated protein docking of the transmembrane
model of IGF2R with the crystal structure of CD20 predicts the bind-
ing pocket and identifies the residue critical for the binding. Struc-
ture of IGF2R with IGF2 compared to docking poses of epitope 3
shows that CD20 binds IGF2R domain 11 in the IGF2 binding site.
This binding site region consists of a hydrophobic pocket centred on
the CD loop, surrounded by polar and charged residues in the AB,
EF and HI loops that complement surface charge on IGF2. The heli-
cal region (residues 178–184) of CD20 mediates the binding to
receptor as well as IGF2 (Fig 2A). Indeed, Tyr18 of CD20 acts as an
anchor making contact with the hydrophobic cluster Tyr1542, Phe
1567 and Leu 1629 of IGF2R domain 11 (Fig 2B), while for IGF2 the
Phe19 of IGF2 is involved in the hydrophobic interaction (Fig 2C).
Site-directed mutagenesis and structural studies have been shown
that Phe 19 is important for IGF2R binding (Chuprin et al, 2015).
CD20 (Swiss-Prot code: P11836) is an integral membrane protein
with intracellular N- and C-termini, four transmembrane spans
(TM1–4) and an extracellular domain located between TM3 and
TM4. Its only extracellular portions are two short loops located at
positions 72–80 and 142–182. Mutagenesis and epitope mapping
studies identified two CD20 epitopes in these extracellular domains.
Epitope 2 spans residues 146–160, while epitope 3 spans residues
168–175. The X-ray structures of the Fab fragment in the complex
with epitope 3 mimicked the large extracellular loop of CD20. The
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complex structure of human IGF2R domains 11–13, which bind to
IGF2 (PDB code 2v5p), is also available. Using a protein–protein
docking procedure, we evaluated the IGF2R-CD20 epitope 3 interac-
tion using the ClusPro server. Four initial CD20 epitope 3 conforma-
tions (obtained with the PDB codes 2osl, 3bky and 3pp4) and one
IGF2R conformation were used as the starting structures for the
docking simulations. Computational steps were performed as
follows: (i) rigid-body docking by sampling billions of conforma-
tions, (ii) RMSD-based clustering of the 1,000 structures with the
lowest energy to find highly populated clusters that will represent
the most likely models of the complex and (iii) refinement of the
selected structures using energy minimization. For each simulation,
ClusPro returned ten clusters with low energy, and a representative
pose was chosen from the most populated cluster with the lowest
energy on visual inspection (Fig 2C). In co-immunoprecipitation
experiments, the IGF2R protein formed a stable complex with CD20
(Fig 2E), and shCD20 abolished or decreased the ability of IGF2R to
interact with CD20 (Fig 2E). These findings suggest that IGF2R and
CD20 share a common hydrophobic binding motif that stabilizes
their association. Moreover, over-expression of CD20 increased the
expression of IGF2R in C2C12 myoblasts (Fig 2D). These results
verify that functional interactions occur between CD20 and IGF2R
during myoblast differentiation. The expression of early and late dif-
ferentiation myogenic markers demonstrated that myoblasts started
to express myogenin after 2 days in differentiation medium (DM)
and that its expression peaked after 4 days before decreasing after
A
C
F G H
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Figure 1. IGF2R blockade results in CD20 phosphorylation.
A RT–PCR expression and quantification of IGF1, IGF1Rb and IGF2 levels in untreated C2C12 and shCD20 C2C12 myoblasts and 10 nM IGF1-treated C2C12 and over-
expressing CD20 C2C12 myoblasts. Each experiment was replicated independently four times. Two-way ANOVA. ****P < 0.0001. All values are expressed as the
mean  SEM.
B Immunofluorescence for IGF2 (in green) in untreated and 10 nM IGF1-treated C2C12 myoblasts. Scale bars = 75 lm.
C–E Representative CD20 immunoprecipitation using anti-pSer + pThr in (C) C2C12 cells treated with IGF1 for 2 h or overnight (ON), (D) sh-empty (shCTR)- and
shCD20-treated C2C12 cells treated with anti-Flag and 10 nM anti-IGF2R, (E) C2C12 cells treated with IGF1 and IGF2, as indicated. Densitometric analysis of data is
expressed as the ratio of CD20/vinculin or pSer + pThr/CD20 and is shown normalized to vinculin in arbitrary units in the lower panels. Two-way ANOVA.
*P < 0.05; **P < 0.01; ****P < 0.0001. Each experiment was performed in triplicate wells. All values are expressed as the mean  SEM.
F Representative WB of IGF2R and phosphorylated IGF2R (pIGF2R) in untreated, shCD20-treated and anti-IGF2R-treated C2C12 cells. Densitometric analysis of data is
expressed as the ratio of IGF2R/actin or pIGF2R/IGF2R in arbitrary units in the lower panels. One-way ANOVA. *P < 0.05. Each experiment was performed in
triplicate wells. All values are expressed as the mean  SEM.
G IGF2R immunoprecipitation products were immunoblotted for Gai2 and WB expression of IGF2R in untreated, IGF2-treated, anti-IGF2R-treated and IGF2 + anti-
IGF2R-treated C2C12 cells. Densitometric analysis of data is expressed as the ratio of Gai2/IGF2R in arbitrary units in the lower panel. Each experiment was
performed in triplicate wells. All values are expressed as the mean  SEM.
H Representative WB of IGF1Rb and IGF1Rb immunoprecipitation products immunoblotted for pTyr in untreated, IGF2-treated and IGF2 + anti-IGF2R-treated (1:500,
1:1,000 and 1:2,000 dilutions of anti-IGF2R) C2C12 cells (cells were treated for 2 and 24 h). Densitometric analysis of data is expressed as the ratio of pTYR/IGF1Rb
in arbitrary units in the lower panel. Each experiment was performed in triplicate wells. All values are expressed as the mean  SEM.
Source data are available online for this figure.
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6 days of differentiation (Fig 2F–H). Accordingly, the expression of
MyHC was first observed on day 4 and persisted at day 6. Myoblasts
exposed to blockade of IGF2R showed a significant increase in the
expression of early and late differentiation markers. Myogenin
expression was significantly higher at day 2 in treated than in
untreated cells, as was MyHC expression, which was detectable at
the same time points, peaked at 4 days and then decreased at day 6
(Fig 2G and H). Surprisingly, treatment with shCD20 resulted in a
consistent delay in myoblast differentiation after IFG2R blockade:
myogenin expression was undetectable after 2 days of differentia-
tion and was only slightly detectable on day 4, whereas MyHC was
not expressed at any of the evaluated time points (Fig 2G and H).
Fusion index analysis confirmed the loss of differentiation potential
in shCD20-treated C2C12 myoblasts exposed to IGF2R blockade
(Fig 2G). Moreover, IGF2R blockade-induced C2C12 myotubes were
found to be longer and to have a low number of nuclei per fibre
compared to untreated C2C12 myotubes which appeared larger with
a high number of nuclei per fibre (Fig 2F), indicating that muscle
differentiation of C2C12 myoblasts exposed to IGF2R blockade
proceeded for those cells that started prematurely to fuse. In line,
human primary myoblasts (HSkM) treated with anti-IGF2R were
able to form myotubes with long shape and low number of nuclei
especially after 6 days of differentiation (Fig 2F). Moreover, HSkM
exposed to IGF2R blockade showed increased expression of
myogenin and MyHC between days 2 and 4 with fusion capacity
similar to C2C12 treated with anti-IGF2R (Fig 2G and H). Together,
these data provide evidence indicating the possibility that the timing
of expression of early and late differentiation markers is altered in
C2C12 and HSkM myoblasts exposed to IGF2R blockade and that
CD20 silencing dampens the effect of IGF2R blockade. We reasoned
that this could depend either on a premature differentiation of
myoblasts exposed to IGF2R blockade or on the presence of a mixed
population of proliferating and differentiating cells.
IGF2R and CD20 interactions modulate intracellular Ca2+
concentrations and activate the CAMKII/calcineurin/NFAT
signalling pathway of myoblasts
We thus investigated the mechanisms that could potentially mediate
IGF2R blockade-induced myoblast differentiation. Western blotting
showed that blockade of IGF2R remarkably increased CAMKII phos-
phorylation in C2C12 myoblasts but did not affect shCD20-treated
C2C12 myoblasts (Fig EV2A and B). Conversely, blockade of IGF2R
decreased the expression of calcineurin in C2C12 myoblasts
(Fig EV2C and D). Moreover, the nuclear expression of NFAT was
increased in store depletion (SD) and SD+anti-IGF2R-treated
A
D
F
H
E
G
B C Figure 2. IGF2R binding to CD20 is relevant for myogenic differentiation.
A–C Bioinformatic prediction of IGF2R and CD20 cross-reactivity. Cartoon
representation of the interaction of IGF2 (yellow) and IGF2R domain 11
complex from X-ray structure (PDB code 2v5p). IGF2R domain 11 AB, CD,
EF and HI loops and residues (shown in sticks format) involved in the
hydrophobic interactions are shown (A). Cartoon representation of the
IGF2R domain 11–CD20 (lime) complex obtained from docking
simulations and residues involved in hydrophobic interactions is shown
in stick format (B). The structure of IGF2R (in red) and IGF2 (green) is
shown compared to docking poses of epitope 3. These data show that
the helical region (residues 178–184) of the epitope mediates binding to
the receptor as well as IGF2. The C-terminal helix of epitope 3 partially
overlaps the first a-helix of IGF2. ClusPro-dock IGF2R-CD20 binding
epitope poses corresponding to PDB codes 2v5p-2oslP, 2v5p-2oslQ and
2v5p-3pp4P are coloured in yellow, blue and cyan, respectively (C).
D Over-expressing CD20 in C2C12 myoblasts that co-expressed CD20 (in
green) and IGF2R (in red). DAPI-labelled nuclei are shown in blue. Scale
bars = 75 lm.
E Representative CD20 and IGF2R immunoprecipitation products
immunoblotted for IGF2R and CD20, respectively, in untreated and
shCD20-treated C2C12 cell membranes and whole lysates of proteins.
The immunoprecipitation output is shown as IP neg.
F Myotube immunofluorescence of cells in proliferation medium (P.M.) and
after 2, 4 and 6 days of myogenic differentiation in serum-free medium.
Control (untreated), shCD20-treated C2C12 cells, C2C12 and HSkM
myoblasts pre-treated with anti-IGF2R for 24 h were stained. Desmin-
positive myotubes are shown in green. Scale bars = 75 lm.
G Fusion index quantification after 6 days of differentiation. One-way
ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Each
experiment was performed in triplicate wells. All values are expressed as
mean  SEM.
H Representative WB of anti-myogenin, anti-Myf5, anti-MyHC and anti-b-
actin in total protein lysates obtained from untreated, shCD20-treated
C2C12 cells, and C2C12 and HSkM myoblasts pre-treated with anti-IGF2R
for 24 h; cells were collected under P.M. and after 2, 4 and 6 days of
myogenic differentiation. Densitometric analysis of WB data expressed as
the ratio of the indicated antibody/b-actin in arbitrary units. Two-way
ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 in
comparison with the results obtained in untreated cells at the
corresponding time point. ##P < 0.01; ###P < 0.001; ####P < 0.0001 in
comparison with the results obtained in shCD20-treated C2C12 cells at
the corresponding time point. Each experiment was performed in
triplicate wells. All values are expressed as the mean  SEM.
Source data are available online for this figure.
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C2C12 myoblasts, and this change was correlated with an increase
in the level of MyoD (Fig EV2E and F). These data suggest that SD
and blockade of IGF2R in SD myoblasts activate CaMKII and nega-
tively regulate calcineurin whereas the net effect is to induce NFAT
to activate nuclear MyoD expression and myoblast differentiation.
To determine whether IGF2R and CD20 interactions may modu-
late intracellular Ca2+ concentrations, we measured Fluo-4-loaded
C2C12 and C2C12 shCD20 myoblasts previously treated with or
without anti-IGF2R antibodies. Cells treated with anti-FLAG antibod-
ies were assayed as a negative control. The percentage of Fluo-4+
C2C12 cells was significantly higher in cells treated with anti-IGF2R
antibodies than in both untreated (P < 0.05) and anti-FLAG
(P < 0.005)-exposed cells (untreated: 20.19%  8.12%; anti-FLAG:
15.3%  3.10%; anti-IGF2R: 36.4%  11.5%) (Fig EV3A), suggest-
ing that myoblasts are responsive to SOCE after IGF2R binding.
Additionally, the mean fluorescence intensity (a value directly
proportional to the amount of intracellular Ca2+) was slightly higher
in anti-IGF2R-treated C2C12 myoblasts than in untreated cells (un-
treated: 28.07  5.31; anti-IGF2R: 35.02  9.14) (P < 0.05)
(Fig EV3B), indicating that SOC currents were modestly increased
by exposure to anti-IGF2R antibodies. Importantly, the proportion of
CD20+ cells in the total number of Fluo-4+ C2C12 cells was quanti-
fied, and on average, 32% of cells were double-positive (Fig EV3C).
However, Fluo-4CD20+ cells were 57.4%, indicating that not all of
the C2C12 myoblasts that expressed CD20 were responsive to SOCE
under these experimental conditions. Together, these data indicate
that responsiveness to SOCE can be unlocked and SOC influx
enhanced by targeting CD20 in C2C12 myoblasts, supporting the
notion that CD20 acts as an SOCE modulator in these cells. We next
carried out experiments to investigate how the loss of CD20 affects
SOCE in C2C12 myoblasts. Measurement of SOCE showed that a
significantly higher percentage of Fluo-4+ cells were observed in the
CD20-silenced than in untreated C2C12 myoblasts, indicating that
responsiveness to SOCE was consistently enhanced in these cells
(untreated: 33.8%  2.33; shRNA CD20: 46.8%  2.11; P < 0.05).
Importantly, there was no significant difference in the behaviour of
cells infected with shRNA construct that encoded a scrambled
sequence and untreated C2C12 myoblasts, confirming the specificity
of this phenomenon (shRNA CTR: 18.9%  9.88; Fig EV3D). Given
that the knockdown efficiency was below 70%, exposure to the
anti-CD20 antibody was expected to at least partially recapitulate
the effects observed in untreated (not silenced) C2C12 myoblasts.
Treatment with anti-IGF2R antibodies also increased the proportion
of Fluo-4+ cells in CD20-silenced C2C12 myoblasts (Fig EV3D). In
contrast, there was no significant difference in mean fluorescence
intensity between untreated and CD20-silenced C2C12 myoblasts
regardless of whether they were or were not exposed to anti-IGF2R
antibodies, suggesting that the achieved knockdown efficiency was
not sufficient to affect SOC influx amplitudes (Fig EV3E).
IGF2R blockade regulates Ca2+ homeostasis of myoblasts via
store-operated calcium entry (SOCE) and SERCA1
We next carried out continuous fluorescence recording experiments
to address whether targeting CD20 would modulate the magnitude
of SOCE in C2C12 myoblasts. Fluo-4-loaded cells were imaged in
real time beginning during the intracellular Ca2+ SD step and
throughout the process during which the external Ca2+
concentration was increased so that both the preparative SD and
effective (Ca2+ re-entry) phases of SOCE were monitored. Compared
to untreated cells, the anti-IGF2R-treated myoblasts (n = 133) had a
significantly lower fluorescence profile throughout the imaging
period, indicating that both SD and Ca2+ re-entry were impaired
(Fig EV3F). The effective phase of SOCE was impaired in CD20-
silenced C2C12 myoblasts treated with anti-IGF2R antibodies
(n = 49), suggesting an interaction between IGF2R and CD20 during
the SD step (Fig EV3F). Cells treated with control antibodies (anti-
FLAG; n = 33) or infected with an shRNA encoding a scrambled
sequence (n = 39) behaved in a manner almost identical to that
observed in untreated cells (n = 104 and n = 100, respectively) at
all time points, confirming the specificity of our observations
(Fig EV3H).
To assess whether IGF2R targeting specifically modulated SOCE,
cells were assayed in the presence of the SOC influx inhibitor BTP2.
When the anti-IGF2R-treated (n = 40) and CD20-silenced C2C12
myoblasts (n = 42) were compared to cells receiving the SOCE
blocker alone (n = 48), no difference was observed, suggesting that
IGF2R targeting is ineffective if SOCE does not occur (Fig EV3I). We
further assessed SD efficiency by adding 10 mM caffeine after the
SD protocol. The caffeine-induced intracellular Ca2+ peak was
almost completely abolished in untreated (n = 40) and CD20-
silenced cells (n = 41), demonstrating that SR stores are effectively
emptied. In contrast, a Ca2+ peak was clearly observed in cells
exposed to anti-IGF2R antibodies (n = 46), indicating that SD effi-
ciency was reduced by blockade of IGF2R (Fig EV3G). The impact
of CD20 targeting on the cellular response to a Ca2+-free environ-
ment was also investigated before thapsigargin was added. As
expected, in C2C12 myoblasts (n = 30), the intracellular Ca2+
concentration progressively decreased over time. This decrease was
significantly delayed in anti-IGF2R-treated cells (n = 39), suggesting
a role for CD20 in mediating the cell response to extracellular Ca2+
deprivation (Fig EV3J).
Because the plasma membrane channel ORAI1 is the main
component of SOCE, we investigated its interaction with CD20 and
its expression in SD myoblasts treated with or without anti-IGF2R.
As expected, we found that ORAI1 and CD20 co-immunoprecipitated
(Fig EV3K and L). Blockade of IGF2R increased CD20 expression,
whereas increased CD20 phosphorylation was observed in SD and
SD+anti-IGF2R-treated myoblasts (Fig EV4A and B). Conversely,
CD20 phosphorylation was impaired or reduced in SD shCD20 and
normal myoblasts after IFG2R blockade (Fig EV4A and B). More-
over, the CD20 phosphorylation induced by blocking IGF2R in
myoblasts decreased the interaction between CD20 and ORAI1 in SD
myoblasts and mostly blocked this interaction in SD myoblasts
treated with anti-IGF2R antibodies (Fig EV3J and K), suggesting a
possible interaction between ORAI1 and STIM1 leads to Ca2+
release from intracellular calcium stores in the SR. Interestingly,
SERCA1 expression was increased in ER lysates of anti-IGF2R-
treated SD C2C12 cells compared to the SD+CD20-anti-IGF2R-treated
C2C12 myoblasts (Fig EV4C). Since SOCE modulates SERCA activ-
ity, we tested ATPase hydrolysis and found that the myogenic dif-
ferentiation induced by blockade of IGF2R significantly increases
SERCA activity compared to shCD20 SD+anti-IGF2R cells
(P < 0.0001 after the first 2 min and P < 0.01 after 3 min;
Fig EV4D). The SD and SD+anti-IGF2R showed increased SERCA
activity compared to the untreated C2C12 cells (P < 0.0001 for the
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first 2 min, P < 0.001 after 3 min, P < 0.01 after 4 min, P < 0.05
after 5 min, P < 0.0001 for the first 4 min, P < 0.01 after 5 min and
P < 0.05 after 6 min, respectively; Fig EV4E).
IGF2R is highly expressed in dystrophic muscles
The skeletal muscles of mdx mice exhibited similar CD20 expression
levels but increased IGF2R expression compared to that observed in
C57Bl6/J mice (Fig 3A and C). Similarly, IGF2R expression was
increased in human dystrophic muscles obtained from two DMD
patients compared to healthy human muscles (Fig 3B and E). We
found that the level of CD20 phosphorylation was higher in mdx
muscle and that this change was related to an alteration in IGF2R
expression (Fig 3D and E). Due to its involvement in the transport
of lysosomal enzymes and IGF lysosomal degradation, IGF2R is
continuously recruited to the intracellular space and then recycled
back to the cell membrane, in which only 10–20% of the total IGF2R
protein is localized. For this reason, when we evaluated IGF2R
protein expression levels in skeletal muscle tissues, we performed
WB experiments using both total protein extracts and isolated sarco-
lemma. These expression patterns showed significant increase of
IGF2R in both total and sarcolemmal extracts of the Tibialis Anterior
(TA) and Vastus Medialis (VM) muscle tissues of mdx mice and
DMD patients than those observed in healthy controls (Fig 3 E and
F). Moreover, the pattern of low IGF2R expression in healthy
muscles (Fig 3E and F) may reflect that IGF2 is mainly expressed
during the development and dramatically reduced after birth and in
adult tissues (de Pagter-Holthuizen et al, 1987). No bands were
obtained when GAPDH blotting was performed using isolated sarco-
lemma, confirming the functionality of the isolation protocol.
IGF2R blockade ameliorates muscle function in mdx mice
To study the effects of IGF2R blockade on muscular dystrophy, we
intravenously administered anti-IGF2R antibodies at low (10 lg per
mouse) and high (100 lg per mouse) dosages to 3-month-old mdx
mice for 4 and 9 weeks. This genetically dystrophic mouse model
exhibits dystrophic muscle features and skeletal muscle vascular
regression (Loufrani et al, 2001, 2002, 2004; Williams & Allen,
2007). Morphometric analysis of the TA and VM muscles of anti-
IGF2R-treated mdx mice showed that the levels of typical fibrotic
infiltrate and centrally nucleated fibres were lower than in controls
(Fig EV5). Mdx mice were characterized by high variability in
myofibre size (Fig EV5). The cross-sectional areas (CSAs) of the
myofibres were significantly lower in the muscles of mdx mice
treated with a low dose of anti-IGF2R for 4 weeks (TA:
2,251  33 lm2, n = 10; VM: 1,882  41 lm2, n = 10) than in the
muscles of untreated age-matched mice (TA: 4,476  94 lm2,
n = 10; VM: 1,383  73 lm2, n = 10) (P < 0.0001, one-way
ANOVA analysis of variance with Bonferroni correction). Although
the difference was not significant, a similar reduction in the CSA
A
B
C D
E F
Figure 3. IGF2R is over-expressed in dystrophic muscle.
A Immunofluorescence analysis of CD20 and IGF2R expression (in red) in
the TA muscles of three-month-old C57Bl6/J and mdx mice. Scale
bars = 75 lm.
B IGF2R (green) and sarcomeric actin (magenta) expression in the VM
muscles of two DMD patients. Scale bars = 25 lm.
C, D Representative WB analysis of CD20 and b-actin (C) and pSer + pThr and
GAPDH (D) expression in the TA and VM muscles of C57Bl6/J and mdx
mice (n = 10 mice per group). Densitometry analysis of WB data is
expressed as the CD20/b-actin ratio and pSer + pThr/CD20 ratio in
arbitrary units in the lower panels. One-way ANOVA. ****P < 0.0001. All
values are expressed as the mean  SEM.
E Representative WB analysis of IGF2R and GAPDH expression in total
protein lysates of the human (healthy and DMD) and murine (C57Bl6/J
and mdx) TA and VM muscles (n = 2 per healthy and DMD; n = 10 mice
per group); quantifications are expressed as the IGF2R/GAPDH ratio in
arbitrary units. One-way ANOVA. ***P < 0.001; ****P < 0.0001. All values
are expressed as the mean  SEM.
F Representative WB analysis of IGF2R expression in sarcolemma protein
lysates of the TA and VM muscles of healthy, DMD, C57Bl6/J and mdx
(n = 2 per healthy and DMD; n = 10 mice per group). Densitometry
analysis of IGF2R expression, results are shown as a fold increase, as
indicated in the lower panel in arbitrary units. One-way ANOVA.
*P < 0.05; ****P < 0.0001. All values are expressed as the mean  SEM.
Source data are available online for this figure.
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was observed in the muscles of mdx mice treated with a high dose
of anti-IGF2R for 4 weeks (TA: 2,847  63.5 lm2, n = 10; VM:
1,627  42 lm2, n = 10) compared to the CSAs observed in the
muscles of untreated mdx mice (TA: 4,110  80.3 lm2, n = 10;
VM: 1,668  19 lm2, n = 10; Fig 4A). Moreover, the coefficient of
variation of myofibre area was significantly higher for the muscles
of the anti-IGF2R-treated low dosage mdx mice (TA: 73.22  6.17%
for 4 weeks and 59  5.93% for 9 weeks; VM: 74  4.81% for
4 weeks and 66  3.38% for 9 weeks) than for those of untreated
mdx mice (TA: 50.48  5.4%; VM: 47.37  7.5%) (P < 0.0001, F-
test of variance). However, the areas of the muscle fibres were
significantly higher in the high-dose anti-IGF2R-treated mdx mice
(TA: 4,609  57 lm2 for 4 weeks and 5,188  72 lm2 for 9 weeks;
VM: 3,353  41 lm2 for 4 weeks and 4,704  73 lm2 for 9 weeks)
than in the untreated mice (TA: 2,006  55 lm2; VM:
2,705  41 lm2; Fig 4A). CSA values were also significantly
reduced in the TA (1,709  20 lm2, n = 10) and VM
(2,270  23 lm2) muscles of mdx mice treated with a high dose of
IGF2R for 4 weeks than in the TA (1,885  20.5 lm2) and VM
(3,002  33 lm2) muscles of untreated mdx mice. A similar trend
was observed following 9 weeks of treatment (TA: untreated
2,916  85 lm2 vs. treated 2,096  53 lm2; VM: untreated
2,460  60 lm2 vs. treated 2,773  40 lm2) (P < 0.001, one-way
ANOVA with Bonferroni correction; Fig 4A). Changes in the CSAs
of the muscles of mdx mice suggested that a muscle remodelling
process was induced by anti-IGF2R antibodies. Since the IGF1 and
IGF2 pathways are closely associated with muscle regeneration, we
evaluated the numbers of regenerating neonatal MyHC-positive
fibres and M-cadherin-positive satellite cells in untreated and
IGF2R-treated mdx mice (Fig 4B). We observed that the percentages
of regenerating muscle fibres and the level of neonatal MyHC
expression were significantly higher in the TA and VM of IGF2R-
treated mdx mice than in untreated mdx mice (P < 0.001, one-way
ANOVA with Bonferroni correction) (Fig 4B and C). Moreover, the
number of M-cadherin-positive satellite cells was similarly increased
in the low-dose IGF2R-treated (TA treated for 4 weeks at 20–25/
section and for 9 weeks at 30–40/section; VM treated for 4 weeks at
30–40/section and for 9 weeks at 70–80/section) and high-dose
IGF2R-treated (TA treated for 4 weeks at 30–41/section and for
9 weeks at 47–51/section; VM treated for 4 weeks at 33–46/section
and for 9 weeks at 78–85/section) mdx mice (Fig 4B). To confirm
these findings, we verified whether muscle function was recovered
in the IGF2R-treated mdx mice and evaluated the maximum tetanic
force (Po) normalized for the cross-sectional areas (CSA). We found
that specific force was ameliorated in the anti-IGF2R-treated mdx
mice (P < 0.05, P < 0.001, two-way ANOVA with Bonferroni correc-
tion; Fig 4D). Interestingly, the specific force generated by TA
muscles of mice treated with both low and high doses of anti-IGF2R
and VM muscles of mice treated with low dose of anti-IGF2R for
4 weeks was higher than TA and VM muscles of control C57Bl6/J
(Fig 4D). The increased specific force and the reduction of CSA of
these anti-IGF2R cohorts indicate similar values of Po between anti-
IGF2R-treated mdx and C57Bl6/J mice. Since skeletal muscle perfor-
mance is modulated by SERCA activity and this may explain the
prevalence of myofibres expressing regenerating neonatal MyHC in
IGF2R-treated mdx mice, we compared ATP hydrolysis between
IGF2R-treated and untreated mdx mice. ATP hydrolysis was signifi-
cantly increased in the TA (P < 0.0001 for the first 3 min and
P < 0.01 after 4 and 5 min for low dosages after 4 weeks; P < 0.05
for the first minute for high dosages after 9 weeks) and VM
(P < 0.0001 for the first 4 min, P < 0.001 after 5 min, P < 0.01 after
6 min and P < 0.05 after 7 min for high dosages after 4 weeks, two-
way ANOVA with Bonferroni correction) muscles of 4- and 9-week
low-dose anti-IGF2R-treated mice than in untreated mdx mice
(Fig 4E). The level of active calcineurin A 48 kDa protein expression
was also significantly higher in the TA and VM (P < 0.05,
P < 0.001, two-way ANOVA with Bonferroni correction), whereas
the level of inactive calcineurin A 60 kDa was lower in both the TA
and VM muscles of anti-IGF2R-treated than in untreated mdx mice
(Fig 5A). In contrast, CAMKII phosphorylation was significantly
decreased in both the TA and VM muscles of anti-IGF2R-treated
mdx mice (Fig 5B). Thus, we sought to investigate the effect of this
cascade of signals on the PKC-a downstream signalling pathway.
In response to anti-IGF2R, there was no statistically significant
effect on PKC-a expression or phosphorylation in the TA and VM
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Figure 4. Blockade of IGF2R ameliorates muscular dystrophy.
A Quantification of the relative frequency of myofibre cross-sectional areas
(CSAs) expressed as a frequency distribution in the TA and VM muscles of
untreated mdx mice or mdx mice treated with a low or high dose of
anti-IGF2R for 4 and 9 weeks.
B Quantification of regenerating myofibres as a proportion of centrally
nucleated fibres in the total number of fibres after anti-IGF2R
administration. The quantification of regenerating and M-cadherin-
positive satellite cells per section is shown. One-way ANOVA test,
**P < 0.01; ***P < 0.001; ****P < 0.0001. Each experiment was
performed in triplicate wells, and all values are expressed as the
mean  SEM.
C Representative WB analysis of neonatal myosin heavy-chain (neonatal
MHC) expression and quantification expressed as the ratio of neonatal
MHC/b-actin in untreated mdx mice and mdx mice treated with low and
high doses of anti-IGF2R for 4 and 9 weeks. One-way ANOVA. **P < 0.01;
****P < 0.0001 (n = 10 mice per group). All values are expressed as the
mean  SEM.
D, E Specific force (maximal tetanic force normalized to cross-sectional area,
Po/CSA) from TA and VM muscles (D) and SERCA activity quantified as
ATPase hydrolysis activity vs. min (E) in C57Bl6/J mice, untreated mdx
mice and mdx mice treated with low and high doses of anti-IGF2R for 4
and 9 weeks. One-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001
(n = 10 mice per group). All values are expressed as the mean  SEM.
Source data are available online for this figure.
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muscles (Fig 5C). Thus, we next evaluated CD20 expression and
phosphorylation as an upstream marker of the effect of anti-IGF2R
treatment on signalling. After 4 and 9 weeks, treatment with a low
dose of anti-IGF2R significantly increased CD20 expression in the
TA muscle (P < 0.001, two-way ANOVA with Bonferroni correc-
tion) (Fig 6A). Similarly, CD20 phosphorylation was significantly
higher in TA and VM muscles of treated vs. untreated mice
(P < 0.05, two-way ANOVA with Bonferroni correction) (Fig 6A).
Interestingly, IGF1R phosphorylation was increased in the TA
muscles of mice treated with a low dose of anti-IGF2R and in the
VM muscles of mice treated with both low and high doses of anti-
IGF2R (Fig 6B), suggesting that IGF1 and IGF2 bioavailability was
increased, allowing them to interact with IGF1R, following IGF2R
blockade. To test this possibility, we performed experiments to
evaluate IGF1R phosphorylation after treatment with anti-IGF2R in
3T3 mouse fibroblasts (Fig EV1C–E). IGF1R phosphorylation was
increased after IGF2 was added to the cell cultures (Fig EV1C).
When cells were co-stimulated with IGF2 and anti-IGF2R, the level
of IGF1R tyrosine phosphorylation was higher in than the effect
A
B
Figure 6. IGF2R blockade results in CD20 and IGF1Rb phosphorylation in
mdx mice.
A WB analysis performed in TA and VM muscles of mdx mice treated with
anti-IGF2R using antibodies against CD20, pSer + pThr and vinculin.
Densitometry analysis of data expressed as the pSer + pThr/CD20 and
CD20/vinculin ratio in arbitrary units. One-way ANOVA *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001 for the comparison with untreated
mice (n = 10 mice per group). All values are expressed as the mean  SEM.
B Representative WB analysis performed on TA and VM muscles of mdx mice
treated with anti-IGF2R using anti-IGF1R, anti-phospho-IGF1R and GAPDH.
Densitometry analysis of data expressed as the pIGF1R/IGF1R ratio
normalized to GAPDH content in arbitrary units. One-way ANOVA.
****P < 0.0001 for the comparison with untreated mice (n = 10 mice per
group). All values are expressed as the mean  SEM.
Source data are available online for this figure.
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Figure 5. Calcineurin signalling activation in muscles of mdx mice
treated with anti-IGF2R.
A Representative WB analysis of active 48 kDa and inactive 60 kDa
calcineurin A and b-actin expression in the TA and VM muscles in
untreated C57BL mice, untreated mdx mice and mdx mice treated with low
and high doses of anti-IGF2R for 4 and 9 weeks. Densitometry analysis of
data expressed as ratios of 48 kDa and 60 kDa calcineurin A/b-actin in
arbitrary units. Two-way ANOVA. *P < 0.05; **P < 0.01; ****P < 0.0001
(n = 10 mice per group). All values are expressed as the mean  SEM.
B Representative WB analysis of CAMKII, pCAMKII and GAPDH expression
quantified and shown as CAMKII/GAPDH and pCAMKII/CAMKII ratios in
arbitrary units. Two-way ANOVA. *P < 0.05; **P < 0.01 (n = 10 mice per
group). All values are expressed as the mean  SEM.
C Representative WB analysis of PKCa, pPKCa and b-actin expression levels
quantified and expressed as the PKCa/b-actin and pPKCa/PKCa ratios in
arbitrary units (n = 10 mice per group). All values are expressed as the
mean  SEM.
Source data are available online for this figure.
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observed following treatment with IGF2 alone, confirming the
notion that IGF bioavailability is associated with the activation of
IGF1R (Fig EV1D).
Anti-IGF2R treatment ameliorates vascular rarefaction in the
muscles of mdx mice
Since the IGF2 pathway affects vascular architecture, we examined
the effect of anti-IGF2R on blood vessels in the skeletal muscles of
mdx (n = 10 each group) mice. To analyse the effect of anti-IGF2R
on the vessel structures of dystrophic skeletal muscles, we
performed vessel corrosion casting electron microscopy to examine
capillary architecture and mural cell distribution. Using this
approach, it is possible to identify some of artefacts caused by the
pressure of injection, treatment with dehydration and other manipu-
lations involved in SEM analysis. One of the most frequently
observed types of artefacts is caused by excessive injection pressure
and manifests as vascular leakage of the resin that appears in the
form of roundish or sheet-like conglomerates extending around the
vessels. Although in normal tissues, this event is mostly caused by
the technique itself, in pathological tissues, it may also be caused by
impaired endothelial cell junctions, modifications of the vascular
wall architecture or a rupture in the endothelial cell lining. In
untreated mdx mice, muscle capillaries had no constant direction,
displayed many enlargements and constrictions and were frequently
lacking coverage by pericytes, indicating an immature vessel archi-
tecture (Fig 7A). In contrast, muscle capillaries were linearized in
anti-IGF2R-treated mdx mice (Fig 7A). In particular, in treated VM
muscles, the number of vascular leakages was slightly lower, the
vasculature had a less chaotic and complex architecture, and vessel
coverage by pericytes was improved (Fig 7A). Interestingly, we
found that the number of pericyte-like cells co-expressing NG2 and
CD146 was higher in the treated animals than in the untreated mdx
mice (Fig 7B). NG2+ cells significantly increased in anti-
IGFR2-treated mdx mice after 9 weeks of treatment with a low dose
(one-way ANOVA, P < 0.001) and after 4 and 9 weeks of treatment
with a high dose (one-way ANOVA, P < 0.0001) (Fig 7C). Similarly,
CD146+ cells significantly increase in anti-IGFR2-treated mdx mice
after 9 weeks of treatment with a low dose and after 4 and 9 weeks
of treatment with a high dose (one-way ANOVA, P < 0.0001;
Fig 7C). We also analysed vessel leakage in detail by immunofluo-
rescence and found that the VM muscles of anti-IGF2R-treated mdx
mice exhibited highly uniform alignments of VE-cadherin and CD31-
expressing cells compared to untreated mdx mice (Fig 7E).
Quantification of CD146 and NG2 expression showed that CD146
expression in TA skeletal muscles was significantly increased in the
low-dose anti-IGF2R-treated mice after 4 and 9 weeks (one-way
ANOVA, P < 0.0001 and P < 0.001) and in high-dose anti-IGF2R-
treated mice after 4 weeks (one-way ANOVA, P < 0.01; Fig 7D).
However, NG2 expression was significantly higher in low-dose anti-
IGF2R-treated mice after 9 weeks (one-way ANOVA, P < 0.001) and
in high-dose anti-IGF2R-treated mice after 4 and 9 weeks (one-way
ANOVA, P < 0.05). Interestingly, the expression of CD146 and NG2
in VM muscles showed significant increase in all conditions tested
(Fig 7D). Together, these observations indicate that IGF2R blockade
in mdx mice promoted vascular remodelling and thereby led to
muscle capillary linearization and leakage reduction by increasing
the number of pericytes.
Discussion
In this study, we explored the role(s) of IGF2R in modulating the
activity of endogenous IGFs in the context of dystrophic muscle. We
show that IGF2R is over-expressed in the skeletal muscles of mdx
mice, an animal model of DMD. Intravenous administration of an
A
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Figure 7. IGF2R blockade induces normalization of capillary architecture
in mdx mice.
A Corrosion casting results showing the linearization of capillaries in
IGF2R-treated VM mdx muscles. Pericytes around capillaries are shown in
the insert box. Scale bars = 100 lm.
B, C Representative immunofluorescence results (B) and quantification (C) of
longitudinal sections of VM mdx muscles for the CD146- and NG2-
positive capillaries are shown. Scale bars = 75 lm. One-way ANOVA.
***P < 0.001; ****P < 0.0001 for the comparison with untreated mice
(n = 10 mice per group). All values are expressed as the mean  SEM.
D Representative WB showing CD146 and NG2 expression in total protein
lysates of TA and VM muscles of mdx mice treated with anti-IGF2R.
Densitometry analysis of data expressed as the ratio of the indicated
antibody/b-actin in arbitrary units. One-way ANOVA. *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001 for the comparison with
untreated mice (n = 10 mice per group). All values are expressed as the
mean  SEM.
E Representative VE-cadherin (red) and CD31 (green) expression in small
vessels of VM muscles from untreated mdx and mdx treated with low
dose of anti-IGF2R for 4 weeks. Scale bars = 25 lm.
Source data are available online for this figure.
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anti-IGF2R-neutralizing antibody consistently increased muscle
regeneration and reduced fibrosis and thereby significantly amelio-
rated the dystrophic muscle phenotype. These data strongly argue
that IGF2R inhibition positively affected the regenerative potential
of dystrophic muscle tissues. This conclusion makes physiological
sense in the light of what is known about the role of IGF2R in the
IGF system, in which it is responsible for IGF internalization and
lysosomal degradation. For example, among the variety of
hormones and growth factors known to be involved in myogenesis
regulation, IGFs (including IGF1 and IGF2) exert very critical roles
(Musaro et al, 2001, 2004). Mice deficient in IGF ligands exhibit
muscle hypoplasia and die shortly after birth because they lack the
muscle mass required to inflate their lungs (Liu et al, 1993; Powell-
Braxton et al, 1993), and transgenic mice that over-express IGF1 in
muscles have larger muscle fibres and enhanced muscle strength
during ageing (Coleman et al, 1995; Barton-Davis et al, 1998;
Barton et al, 2002; Kaspar et al, 2003). In cultured muscle cells,
IGF2 levels increase dramatically during myogenesis, IGF2 antisense
oligonucleotides abolished this differentiation process (Florini et al,
1991, 1996), and IGF2 over-expression accelerated myoblast dif-
ferentiation (Stewart et al, 1996). Moreover, Rotwein and colleagues
reported that in cultured muscle cells, secreted IGF2 stimulated
IGF1R, PI3K and Akt to induce the expression of the cyclin-depen-
dent kinase inhibitor p21 and myogenin (Lawlor & Rotwein, 2000;
Wilson & Rotwein, 2007). The muscle impairment observed in DMD
patients is characterized by extremely low regenerative capacity,
fibrosis, fat deposition, inflammatory infiltrates and fibre hypotro-
phy. In recent decades, a number of different approaches have been
investigated to treat DMD. Unfortunately, most therapeutic strate-
gies have been palliative rather than curative. In this context, the
benefits obtained after IGF2R blockade prompted us to explore a
new potential therapeutic approach. In this study, we provide the
first data showing that CD20 binds to the conserved domain 11 of
IGF2R. Importantly, domain 11 was the first of the IGF2R extracellu-
lar regions to be characterized by X-ray crystallography, and it
contains the putative IGF-binding site (Schmidt et al, 1995; Brown
et al, 2002). Our experimental findings provide evidence indicating
that IGF2R specifically interacts with CD20 and blockade of IGF2R
induces CD20 phosphorylation promoting intracellular Ca2+
modifications.
Muscular dystrophies (MD) are often associated with Ca2+
dyshomeostasis. Intracellular Ca2+ ions critically regulate contrac-
tion and force production of muscle fibres by acting as the primary
regulator of the sarcomeric contractile machinery and as a second
messenger in the signal transduction pathways that control muscle
growth, metabolism and pathological remodelling (Berchtold et al,
2001; Bassel-Duby & Olson, 2006). During exercise, Ca2+ is cycled
between the cytosol and the sarcoplasmic reticulum (SR) through a
system by which the Ca2+ pool in the SR is restored by uptake of
extracellular Ca2+ via a mechanism called store-operated Ca2+ entry
(SOCE). Among the proteins known to be involved in the activation
and regulation of SOCE, the two most prominent are STIM1 and
ORAI1. STIM1 spans the SR membrane and, through its SR-hand
domain located in the lumen of the SR cistern, senses the Ca2+
concentration in cellular stores. Depletion of ER calcium results in
the horizontal movement of STIM1 in the SR membrane, causing it
to cluster and interact with the plasma membrane channel-forming
protein ORAI1. This eventually results in Ca2+ entry into the cell.
Replenishment of Ca2+ stores breaks these molecular interactions
and stops Ca2+ influx (Smyth et al, 2010; Gudlur et al, 2013). Inter-
estingly, the CD20 phosphorylation induced by IGF2R blockade in
myoblasts decreased the interaction between CD20 and ORAI1 in
store-depleted myoblasts, and this effect was increased in store-
depleted myoblasts treated with anti-IGF2R. These data corroborate
the hypothesis (Ju et al, 2003; Parolini et al, 2012) that CD20 inter-
acts with ORAI1 in the muscle plasma membrane and that its phos-
phorylation promotes the interaction between ORAI1 and STIM1,
which mediates Ca2+ release from intracellular calcium stores in
the SR.
Reuptake of Ca2+ ions in the SR during excitation–contraction
(EC) coupling is regulated by the ATP-dependent sarcoplasmic/
endoplasmic reticulum calcium ATPase pump (SERCA1; Rossi &
Dirksen, 2006). Interestingly, SERCA activity has been reported to
be reduced in dystrophic muscle (Kargacin & Kargacin, 1996; Divet
& Huchet-Cadiou, 2002; Divet et al, 2005), and this effect is likely
responsible for some characteristics of defective Ca2+ handling
observed in MD because it leads to higher cytoplasmic levels of
Ca2+ and increases cellular necrosis via calpain activation and
increased mitochondrial permeability (Odermatt et al, 1996; Dorn
& Molkentin, 2004; Periasamy & Kalyanasundaram, 2007;
Goonasekera et al, 2011). Blockade of IGF2R activated SERCA1
and enhanced SR Ca2+ uptake, promoting premature differentiation
of myoblasts and correcting Ca2+ overload; these effects likely
induced muscle regeneration and vessel development in dystrophic
mdx mice. CaMKII can activate the reuptake of Ca2+ ions in the SR
regulating the SERCA1 (Damiani et al, 2000; Sacchetto et al, 2000).
The results of IGF2R blockade of myoblasts suggest that calci-
neurin inhibits CaMKII-mediated phosphorylation, and the inhibi-
tion of calcineurin increases phospho-CaMKII, which results in the
stimulation of CaMKII-dependent cellular actions. Otherwise, the
IGF2R blockade of mdx mice leads to negative regulation of
CaMKII and activation of calcineurin. The calcineurin is involved
in the control of skeletal myofibre specialization and can transform
type II fibres into type I fibres in a dose-dependent manner, and
CaMK acts synergistically with calcineurin to activate slow and
oxidative fibre-specific gene expression in cultured myoblasts (Wu
et al, 2000). Previous report suggested that CaMKII-mediated
processes were abolished by calcineurin in skeletal muscle (Wu
et al, 2002). As for Ca2+ release from intracellular stores, calci-
neurin is directly involved in its regulation and calcineurin inhibi-
tors lead to a higher probability of the ryanodine receptor (RyR)/
Ca2+-release channels being open (Bandyopadhyay et al, 2000;
Bultynck et al, 2003).
Moreover, calcineurin dephosphorylates nuclear factor of acti-
vated T cells (NFAT) hereby regulating its nuclear localization and
facilitates the increased expression of genes involved in myogenic
programme.
Our results further support the idea that blockade of IGF2R
increases intracellular Ca2+ of myoblasts activating cytoplasmic
signalling cascades with opposite effects on calcineurin activity, and
the net effect is NFAT dephosphorylation and translocation into the
nucleus. Finally, mechanical analysis of intact muscles revealed that
muscle force was strongly increased in anti-IGF2R-treated mdx mice
and these data correlated to increased SERCA1 activity. It is reason-
able to conclude from these findings that the increased muscle force
observed in these mice represents the result of a synergy among all
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the benefits promoted by anti-IGF2R treatment in dystrophic muscle
tissue.
Anti-IGF2R binding to domain 11 of IGF2R activates IGF2R-Gai2
interactions and prevents it from interaction with IGF2. This latter
leads to a decrease in the degradation and a consequential increase
in the bioavailability of IGF2 for IGF1R interactions with consequent
IGF1R phosphorylation, which recruits the PI3-K/Akt/mTOR signal-
ling axis to regulate the expression of skeletal muscle-specific genes,
that are associated with myogenic differentiation. The IGF1-induced
pathway also increases Ca2+ influx via SOCE activation (Berridge,
1995; Parekh & Penner, 1997; Barritt, 1999). Interestingly, PI3-K
regulates the CD20 phosphorylation (Ju et al, 2003; Balaji et al,
2018). Thus, blockade of IGF2R reestablished the correct oscillating
pattern of Ca2+ ion levels in the microenvironment of myofibrils
and protects from MD acting on different mechanisms of dystrophic
muscles.
In line with these observations, we found that in vivo blockade
of IGF2R resulted in a significant remodelling of the characteristi-
cally disorganized (i.e. enlarged or constricted) or immature capil-
laries and microvessels that surround muscle fibres in untreated
mdx mice. This effect can be explained, at least in part, by the
increase in the number of pericyte-like cells with a perivascular
localization observed in anti-IGF2R-treated dystrophic muscles. It is
important to note that vascular normalization represents a substan-
tial improvement in the context of degenerating dystrophic muscle
as this condition can have a serious influence on inflammatory cell
migration, nutrient supply and tissue oxygenation; hence, normal-
ization plays a central role in improving the observed dystrophic
muscle phenotypes.
In summary, we provide the first evidence demonstrating that
IGF2R is over-expressed in DMD and mdx muscles and that
systemic administration of an anti-IGF2R-neutralizing antibody
resulted in the recovery of the dystrophic muscle phenotype,
ameliorated vascular architecture defects and improved muscle
force. Importantly, we provide evidence of physical and functional
interactions between IGF2R and CD20. Perturbing this interaction
with anti-IGF2R increased IGF bioavailability to IGF1R and reduced
the intracellular Ca2+ concentration in dystrophic muscle cells,
eventually resulting in an extremely significant amelioration of
dystrophic muscle histology and vasculature defects and force
performance. We are firmly convinced that increasing our under-
standing of the contribution of aberrant IGF2R expression to the
pathophysiology of DMD will ultimately lead to the development of
novel therapeutic approaches. Even if side effects are not comple-
tely avoidable, blockade of IGF2R in DMD patients could represent
an encouraging starting point for the development of new biological
therapies for DMD.
Materials and Methods
Ethics statement
All procedures involving living animals were performed in accor-
dance with Italian law (D.L.vo 116/92 and subsequent additions),
which conforms to the European Union guidelines. The use of
animals in this study was authorized by the National Ministry of
Health (protocol number 10/13–2014/2015). Details on animal
welfare and steps taken to ameliorate suffering are included below.
Muscle biopsies from two DMD patients (10 and 11 years old) and
two healthy subjects (19 and 22 years old) were obtained after
informed consent of each patient (or patient’s parents) was given
to donate the biopsy to the Telethon Biobank (GTB12001) for
research purposes. The research procedures described were
approved by the ethics committee of the University of Milan
(CR937-G). This study was performed in accordance with Interna-
tional Conference on Harmonisation of Good Clinical Practice
guidelines, the Declaration of Helsinki (2008) and the European
Directive 2001/20/EC.
Animal models and in vivo experiments
Animals were obtained from Charles River Laboratories Interna-
tional, Inc. (Calco, Italy). Normal (C57BL6/J) and dystrophic (mdx
C57BL6/10ScSn-DMDmdx/J) male mice were used throughout this
study. We decided to use only males in order to eliminate the sex
variable from the randomization procedure. All mice were fed ad li-
bitum and allowed continuous access to tap water. Cage population
was limited to maximum four animals each to ensure the health
and welfare of animals; equipments and facilities were joined into
the cages to ameliorate environmental conditions. Animals were
deeply anaesthetized with 2% avertin (0.015 ml/kg) prior to sacri-
fice by cervical dislocation, and all efforts were made to minimize
suffering. Three-month-old mice weighing 20 g were systemically
injected into the tail vein with 10 lg (low dose) or 100 lg (high
dose) of Polyclonal Goat IgG Anti-IGF2R (AF2447, R&D Systems,
Minneapolis, MN) (Chen et al, 2011; Lee et al, 2015) and treated
for 4 or 9 weeks. In the control group, the same number of animals
received either no treatment or an injection of a sodium chloride
solution (0.9%). Dynamic light scatter and nanotracking analysis
(NTA) was performed on anti-IGF2R formulation as a precaution-
ary measure to exclude the presence of aggregates triggering
immune response (Appendix Fig S1A and B). To minimize selec-
tion bias, blinding was maintained during and after the interven-
tion so that people that administered the treatment to the animals
and take care of them afterwards were unaware of the treatments.
To maintain the lowest possibility to introduce differences in the
characteristics of animals allocated to treatment groups, the respon-
sible of the experiments did not reveal the allocation sequence to
the people that conducted the experiments until the data were anal-
ysed. In order to rule out the possibility of misleading immunoreac-
tivity against goat polyclonal anti-IGF2R, blood samples of
untreated and treated mdx mice were collected and stored for
ELISA detection of circulating anti-goat antibodies (Appendix Fig
S1C). Recognition of light- and heavy-chain goat immunoglobulins
of anti-IGF2R were confirmed in muscles of mdx after 4 and
9 weeks of treatment (Appendix Fig S1D). All treated animals did
not display any obvious clinical signs of immune reaction against
goat anti-IGF2R treatment.
Cell line treatments and myogenic differentiation
The C2C12 mouse myoblast cell line was commercially obtained
from the ATCC (ATCC CRL1772TM). Cells were tested 1 day before
and during the experiments to exclude mycoplasma contamination.
The culture medium (DMEM with 10% FBS; Thermo Fisher
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Scientific) was supplemented with 1 nM or 10 nM recombinant
IGF1 (Tebu-bio, France) or 10 ng/ml or 100 ng/ml recombinant
IGF2 (Sigma-Aldrich, Germany), and the cultures were then incu-
bated for 2 h or overnight (ON). Anti-CD20 (sc-7736 I20, Santa Cruz
Biotechnology, USA), anti-FLAG (F-7425 Sigma-Aldrich) or anti-
IGF2R (MAB2447, R&D Systems, USA) antibodies were added at
4 lg/ml to the C2C12 culture medium, and the cultures were incu-
bated for 24 h. Human skeletal muscle myoblasts HSkM were
purchased from Gibco (Thermo Fisher, A12555) and thawed in
culture medium. HSkMs were then treated for 24 h with anti-IGF2R
at 4 lg/ml. To induce myogenic differentiation in murine and
human myoblasts, the culture medium was serum-depleted (final
concentration, 2%), and the cells were harvested after 2, 4 and
6 days. ShCD20 (sc-29973-v) and scramble ShCTR (sc-108080) RNA
particles were purchased from Santa Cruz Biotechnology. C2C12
cells were infected at a multiplicity of infection (MOI) of 10 in tripli-
cate wells. Twenty-four hours post-transduction, fresh medium was
added to each well, and the cells were maintained at 37°C in 5%
CO2. Infected cells were selected using puromycin (2 lg/ml) for
3 weeks, and silencing efficiency was evaluated by RT–PCR. The
lentiviral vector used to induce CD20 over-expression was produced
by GeneTarget Inc (USA). The target gene (mouse CD20/MS4a1
chr19:11,250,603–11,266,151) was obtained from a gene bank and
subcloned into an expression lentivector using Eco cloning technol-
ogy (a non-enzyme-based cloning technique). The target gene was
expressed under the CMV early enhancer/chicken b-actin [CAG]
promoter. The RFP-Puromycin reporter gene was expressed under a
Rous sarcoma virus [Rsv] promoter. Thus, the target and reporter
genes were independently expressed by two different promoters.
Cells were infected ON at an MOI of 10. Infected cells were selected
using puromycin linked to RFP. An empty vector was included as a
control (see Appendix Fig S2).
RT–PCR
To detect IGF2 mRNA, classical RT–PCR was carried out with 1 lg
of cDNA as described in Benchaouir et al (2007) with primers listed
in Appendix Table S1. After 36 cycles of amplification (94°C/2 min,
92°C/1 min, 66°C/2 min and 72°C/2 min), PCR products were anal-
ysed on 2% agarose gels.
Sarcoplasmic reticulum isolation
The sarcoplasmic membrane was isolated in accordance with previ-
ously described methods (Parolini et al, 2009). Briefly, vastus medi-
alis (VM) or tibialis anterior (TA) muscles were put in ice-cold
homogenization buffer (250 mM sucrose and 5 mM HEPES pH 7 in
0.2% NaN3) supplemented with complete protease inhibitor cocktail
(Sigma-Aldrich) and homogenized with an electric homogenizer.
The homogenates were then centrifuged at 5,500 g for 10 min at
4°C. The supernatants were harvested and centrifuged at 12,500 g
for 18 min at 4°C. The pellets were discarded, and the supernatants
were centrifuged again at 12,500 g for 18 min at 4°C. The super-
natants were then transferred into ultracentrifuge tubes and centri-
fuged at 50,000 g for 1 h at 4°C. The pellets were resuspended in
homogenization buffer supplemented with 600 mM KCl and
complete protease inhibitor cocktail (Sigma-Aldrich) and incubated
for 30 min on ice. The samples were then centrifuged at 15,000 g
for 10 min at 4°C. The resulting supernatants were centrifuged at
50,000 g for 1 h at 4°C. The final pellets were dissolved in homoge-
nization buffer. The protein content was determined by standard
BCA assays as in Parolini et al (2009).
SERCA activity
Sarco/endoplasmic reticulum Ca2+-ATPase activity was measured
based on inorganic phosphate production using a commercially
available kit (Nanjing Jiancheng Bioengineering Institute, China)
according to the manufacturer’s instructions. Endoplasmic reticu-
lum (ER) fraction was obtained as described above, the protein
concentration of the ER fraction was quantified, and the enzymatic
activity of SERCA pumps was measured by an NADH-coupled assay
(Warren et al, 1974; Strosova et al, 2011; Viskupicova et al, 2015).
The SERCA-catalysed rate of ATP hydrolysis coupled to the oxida-
tion of NADH was measured spectroscopically at a wavelength of
340 nm at PerkinElmer Wallac VICTOR2 Multi-label Counter 1420.
Cell lysates were prepared in SERCA lysate buffer (250 mM sucrose,
5 mM HEPES pH 7, 0.2% NaN3 supplemented with cOmplete Roche
protease inhibitors); the lysate was used to measure SERCA activity.
The SERCA preparation (final concentration 20 lg protein/well of
96 wells) was added to the assay mixture (100 mM KCl, 40 mM
Hepes pH 7.2, 15 mM MgCl2, 5.1 mM MgSO4, 10 mM NaN3, 5 mM
phosphoenolpyruvate, 1 mM EGTA, 5 lM calcimycin, 0.15 mM
NaDH, 1 mM CaCl2, 20 U/ml pyruvate kinase, 20 U/ml lactate
dehydrogenase). The reaction was started by addition of ATP (final
concentration 5 mM). The reaction rate was determined spectro-
scopically by measuring the decrease in NADH absorbance at
340 nm, at 25°C for 20 min. Specific SERCA activity (IU/mg; i.e.
lmol substrate/min/mg of protein) was calculated using the follow-
ing equation:
IU
mg
¼ DA340 nm  V
6:22m
where DA340 nm represent the variation of absorbance at 340 nm
per min, V is the volume of the reaction mixture (mL),
6.22 × 103 L/mol/cm is the absorption coefficient for NADH, and
m represents the total amount of protein in the reaction mixture
(mg).
Western blot (WB) analysis
To prepare total protein extracts, cells (C2C12, HSkM and 3T3),
murine muscles (TA and VM muscles of C57BL and mdx mice) and
biopsies of human biceps–brachialis form, healthy and DMD
patients were homogenized with an electric homogenizer using
RIPA buffer (0.1% SDS, 1% sodium deoxycholate, 1% Triton X-
100, 50 mM Tris–HCl pH 8 and 150 mM NaCl) supplemented with
complete protease inhibitor cocktail (Sigma-Aldrich) and PhosSTOP
(Sigma-Aldrich) and then centrifuged at 18,900 g for 13 min. The
supernatants were collected and stored at 20°C until analysed.
For WB analyses of C2C12 cell lysates, cells were collected by
trypsinization, washed twice with ice-cold PBS, lysed in NP-40
buffer (150 mM NaCl, 1% NP-40 and Tris–HCl 50 mM, pH 8.0)
supplemented with complete protease inhibitor cocktail (Sigma-
Aldrich) and PhosSTOP (Sigma-Aldrich) and then centrifuged at
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18,900 g for 13 min. Supernatants were collected and stored at
20°C until analysed. The total protein concentration was deter-
mined by standard BCA assays and quantified with a Glomax
Microplate Luminometer (Promega, USA). The lysates were diluted
in Laemmli sample buffer (4×) containing b-mercaptoethanol and
boiled for 10 min. Total protein extracts and those obtained from
isolated sarcolemma samples (see above) were separated on poly-
acrylamide gels and then transferred to supported nitrocellulose
membranes (Bio-Rad Laboratories, USA). The filters were saturated
in blocking solution (10 mM Tris pH 7.4, 154 mM NaCl, 1% BSA,
10% horse serum, 0.075% Tween-20). Primary antibodies were as
follows: anti-CD20 (1:500; sc-7736 M-20, Santa Cruz), anti-
Myogenin (1:250; cat. 556358, BD Biosciences, USA), anti-Myf5
(1:500; C-20 sc-302, Santa Cruz), anti-MyoD (1:1,000; 554130, BD
Pharmingen), anti-NFAT (1:1,000; 4998, Cell Signalling, the Nether-
lands), anti-ORAI1 (1:1,000; SAB3500412, Sigma-Aldrich), anti-b-
actin (1:1,000; A2066, Sigma-Aldrich), anti-IGF2R (1:500; sc-14413
K21, Santa Cruz), anti-GAPDH (1:1,000; V18 sc-47724, Santa Cruz),
anti-CamKII (1:1,000; ab52476, Abcam), anti-pCAMKII Thr286
(1:1,000; MA1-047, Thermo Fisher, USA), anti-PKCa (1:1,000;
610107, BD Biosciences), anti-pPKCa Ser 657 (1:1,000; 06-822,
Millipore, USA), anti-IGF1Rb (1:200; sc-390130, Santa Cruz), anti-
phospho-IGF1R (1:200; Tyr1161/Tyr1165/Tyr1166, ABE 332, Milli-
pore), anti-Calcineurin A (1:500; ab3673, Abcam, United Kingdom),
anti-pSer (1:500; 1C8 sc-81515, Santa Cruz), anti-pThr (1:500; H-2
sc-5267, Santa Cruz), anti-pIGF2R (1:500; ser2484, Thermo Fisher),
anti-Gai2 (1:400; sc-7276, Santa Cruz), anti-MyHC slow (1:500;
M8421, Sigma-Aldrich), anti-SERCA1 (1:500; sc-515162, Santa
Cruz), anti-CD146 (1:500; MEL-CAM C-20 sc-18492, Santa Cruz),
anti-NG2 (1:500; sc-20162 H-300, Santa Cruz) and anti-vinculin
(1:1,000; MA-11690, Sigma-Aldrich). The membranes were incu-
bated with primary antibodies ON at 4°C, then followed by wash-
ing, detection with horseradish peroxidase (HRP)-conjugated
secondary antibodies (DakoCytomation, USA) and developed by
enhanced chemiluminescence (ECL) (Amersham Biosciences,
USA). Prestained molecular weight markers (Bio-Rad Laboratories)
were run on each gel. Bands were visualized using an Odyssey
Infrared Imaging System (LI-COR Biosciences, USA). Densitometric
analysis was performed using ImageJ software (http://rsbweb.
nih.gov/ij/).
Immunoprecipitation
Total protein extracts were prepared in 1% Nonidet P-40 detergent
buffer (20 mM Tris pH 8, 137 mM NaCl, 2 mM EDTA, 10% glycerol
and cOmplete and PhosSTOP cocktails, Roche). The antibodies
used for immunoprecipitation of anti-CD20 (sc-7736 M-20, Santa
Cruz), anti-ORAI-1 (ab59330, Abcam) and anti-IGF2R (sc-14413
K21, Santa Cruz) were cross-linked to 25 ll of Dynabeads Protein G
(Thermo Fisher) in accordance with the manufacturer’s instructions.
Total protein lysates (1,000–1,500 lg) were incubated with the
appropriate antibody–Dynabeads complexes and mixed ON at 4°C.
The immune complexes were washed three times in 1 × PBS and
the proteins were eluted boiling the complexes in 2 × Laemmli
buffer (Tris 0.5 M pH 6.8; SDS 2%; glycerol 20%; b-mercap-
toethanol; bromophenol blue) for 10 min. Next, the samples were
centrifuged at 10,000 × g for 5 min, and the resulting supernatants
(IP samples) were collected.
Immunofluorescence and immunohistochemistry analysis
CD20 was detected with anti-CD20 antibodies (M-20) (1:20) in
accordance with Parolini et al (2012). Sarcomeric actin was detected
using 647-phalloidin antibody (A22287 Alexa Fluor). IGF2 and
IGF2R were detected using a rabbit and goat polyclonal antibody,
respectively (1:100; sc-5622, H103 and sc-14413, K21, Santa Cruz).
Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI).
Alexa Fluor 488- and 594-conjugated secondary antibodies (1:200,
Abcam) were used. Images were captured using a Leica TCS SP2
confocal system (Leica, Germany). Muscles were removed, frozen
in liquid nitrogen-cooled isopentane and then sectioned on a cryo-
stat (LEICA CM 1850). Serial sections (8-lm-thick) were stained
with haematoxylin and eosin and Azan-Mallory. Images were
captured with a Leica DM6000B optical microscope. The TA and
VM muscles were cut into longitudinal and transverse cryostat
sections (10 lm) and characterized for their expression of endothe-
lial and pericyte markers. The sections were fixed in 100% acetone
or 80% ethanol and incubated for 2 h at room temperature (RT)
with primary antibodies against CD31 (1:50; 550274 BD Bios-
ciences), a-smooth muscle actin (1:400; A2547, Sigma-Aldrich),
desmin (1:50; AB15200 Abcam), NG2 (1:100; AB5320 Chemicon),
CD146 (1:50; Chemicon) and VE-cadherin (1:100; CD144 550548
eBioscience, USA). After the sections were washed with 1 × PBS,
the slides were incubated with FITC- and Alexa Fluor 594-conju-
gated secondary antibodies (1:100; Thermo Fisher, USA) for 1 h at
RT. After immunostaining was completed, the sections were coun-
terstained with DAPI, coverslipped and examined by epifluores-
cence microscopy DMi8 (Leica). Fusion index was calculated as the
ratio of the nuclei number of desmin-positive myotubes (≥ 2 nuclei)
vs. the total number of nuclei analysed (n > 300).
Cytofluorimetric analysis and calcium imaging
Samples from three independent experiments were acquired with a
FACS—Cytomics FC500 (Beckman Coulter, USA). For calcium imag-
ing, C2C12 cells were incubated in DMEM containing 1.5 lM Fluo-
4/AM supplemented with Pluronic-127 (Thermo Fisher) for 45 min
at RT and then submitted to 45 min of de-esterification. Cells where
then incubated with ERY Ca2+ Ø for 15 min supplemented with
10 lM thapsigargin (Sigma-Aldrich), in 5 mM ERY Ca2+ for 5 min
and then analysed with the cytofluorimeter Cytomics FC500 (Beck-
man Coulter) or FACSCanto II (BD Biosciences) by cxp 2.1 software
(BC) and FacsDiva software (BD Biosciences), respectively. In our
experimental design, cells treated with 5 mM ionomycin for 5 min
were included as a positive control. For calcium imaging, C2C12
cells were incubated in DMEM containing 1.5 lM Fluo-4/AM
supplemented with Pluronic-127 (Thermo Fisher) for 45 min at RT,
as previously described (Hamilton et al, 2008), followed by 45 min
of de-esterification. Cells were then incubated with ERY Ca2+ Ø
(155 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM HEPES) for
15 min, supplemented with 10 lM thapsigargin (Sigma-Aldrich) in
5 mM ERY Ca2+ (155 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM
HEPES, 15 mM CaCl2) for 5 min and, then, analysed with a cytoflu-
orimeter Cytomics FC 500 (Beckman Coulter). In our experimental
design, cells treated with 5 mM ionomycin for 5 min were included
as a positive control. The same store depletion and staining protocol
was followed for time-lapse analyses performed with a Nikon
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BioStation IM (Nikon, Japan), where fluorescence images were
collected every 4 min for 32 min. Thirty mM caffeine (Sigma-
Aldrich) treatment was performed on standard depleted cells, and
images were collected every 5 s for 4 min.
Corrosion casting technique
Untreated and treated mdx mice (n = 10 per group) were sacrificed
by a lethal dose of anaesthetic, and intraventricular infusion of
20 ml heparinized solution (19 ml of 0.9% NaCl solution and 1 ml
of heparin) to prevent blood clotting and 10 ml of PBS (Phosphate
Buffered Saline solution) to clear the remaining blood from the
vascular bed and minimize the blood in the reservoirs was
performed. Ten millilitres of an acrylic low-viscosity resin
(MERCOX, SPI Supplies) was mixed with 0.2 ml of catalyser (ben-
zoyl peroxide), diluted (20%) with methyl methacrylate (SPI
Supplies) and then very slowly manually injected (1 ml/min)
through a cannula inserted into the left heart ventricle, which was
then closed with metallic staples to prevent any reflux of the resin.
After the acrylic compound was allowed to partially polymerize for
approximately 10 min, the animal was immersed in a warm water
bath (60°C) for 1 h to complete the hardening process. Next, the
VM or TA muscles were immersed in a 15% KOH solution to digest
all the organic tissues around the vessels. This solution was
changed every day for 1 week, during which the specimens were
washed with distilled water supplemented with 5 ml of mycostatin
to prevent fungal growth. The resulting casts were then dissected
under a scanning electron microscopy (SEM) observations. They
were dehydrated through a graded series of alcohol solutions, dried
at critical point in an Emitech K850 CPD apparatus, mounted on
aluminium stubs on adhesive film and coated with 10 nm of gold in
an Emitech K250 Sputter Coater. Due to their size, some of the spec-
imens needed to be fitted with metallic bridges to maintain good
conduction throughout the stub. The specimens were then observed
in a Philips XL-30 FEG SEM working at 10 kV. Quantitative evalua-
tion of resin leakages from the vessels was performed at 250× in
random fields. Data were then evaluated using common statistical
analysis.
Mechanics of isolated muscles
TA and VM muscle strips obtained from C57BL6 (n = 10) and either
untreated (n = 10) or treated mdx (n = 10) mice were rapidly and
carefully dissected, following the muscle fibre orientation, and
placed in an organ bath filled with Krebs solution (120mM NaCl,
2.4 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 5.6mM glucose, 1.2 mM
KH2PO4 and 24.8 mM NaHCO3; pH 7.4). The bath was bubbled with
95% O2 and 5% CO2 at a constant temperature of 22°C and attached
to a force transducer (Radnoti Organ Bath System, AD Instruments).
Electrical pulses were delivered through platinum electrodes
connected to a stimulator (Tumiati, Italy). Tetanic isometric contrac-
tions were evoked (110 Hz, 500 ms, supramaximal amplitude) at
the length at which the maximal isometric force was observed (Lo),
and the twitch time to peak and maximal tetanic force (Pt) values
were measured. Muscle forces generated, including Pt and maximum
tetanic force (Po), were normalized for the estimated physiological
cross-sectional areas (CSA) of the muscle segment (CSA = muscle
weight/1.056 × Lo; where 1.056 g/cm3 represents the density of
muscle) and expressed in kilonewtons (kN)/m2. All tests were
performed in accordance with D’Antona et al (2007).
Docking experiments
3D structure of IGF2R and epitope 3 of CD20 were retrieved from
the Protein Data Bank (IGF2R-2v5p; epitopes 3 CD20-20sl and
3pp4). To investigate the molecular interactions of IGF2R, epitope 3
of CD20, chain A of 2v5p, chains P and Q of 2osl and chain P of
3pp4 were used in molecular docking studies. Docking simulations
were performed using ClusPro 2.0 (Kozakov et al, 2017). Computa-
tional steps were performed as follows: rigid-body docking using the
Fast Fourier Transform (FFT) correlation approach, root mean
square deviation (RMSD) based on the clustering of structures to
identify highly populated clusters that represented the most likely
models of the complex, and refinement of selected structures using
energy minimization. For each simulation, ClusPro returned clusters
associated with low energy, and a representative sample was chosen
by visual inspection and by selecting the most populated cluster that
had the lowest energy.
Assessment of plasma antibodies reactive against polyclonal goat
anti-mouse IGF2R
Murine antibodies against polyclonal goat anti-mouse IGF2R titres
were measured as previously described, with few modifications
(Mazor et al, 2017). Cheek blood from mdx mice treated for 4 or
9 weeks with low- and high-dose anti-IGF2R antibody was collected
into EDTA-treated tubes (Thermo Fisher Scientific). Samples were
immediately centrifuged at 1,008 g for 5 min for collecting plasma
and stored at 20°C. Plasma from not injected (n.i.) mdx mice was
used as pre-dose control samples. Briefly, ELISA plates (Greiner Bio-
One) were coated with 100 ll of 0.2 mg/ml goat anti-mouse IGF2R
and stored overnight at 4°C. Before use, plates were rinsed exten-
sively with 1× PBS with 0.05% Tween-20 (wash buffer) and then
blocked with 5% BSA in 1× PBS with 0.05% Tween-20 (binding
buffer) for 1 h at room temperature on a plate shaker. Serial dilu-
tions of murine plasma samples were prepared in binding buffer
starting with a 1:10 dilution. 100 ll of serially diluted samples was
then added to the ELISA plates and incubated at room temperature
on the shaker for 2 h. After incubation, the plates were washed
three times with wash buffer and mouse antibodies against IGF2R
were detected with anti-mouse IgG (H + L) HRP (Jackson Immu-
noResearch) (1:3,000 for 1 h at room temperature) and TMB ELISA
substrate high sensitivity (Abcam). The reaction was stopped with
H2SO4 stop solution, and optical density of the wells was read
immediately at a wavelength of 450 nm with subtraction at 650 nm.
Titres were calculated based on a four-parameter logistic curve-fit
graph, and endpoint titre was calculated as the reciprocal of the
highest dilution that gives signal above background absorbance.
Results were expressed as fold changes over pre-dose values.
Dynamic light scatter and nanotracking analysis evaluation of
aggregates into antibody formulation
Dynamic light scatter (DLS) analysis was performed with Zetasizer
Nano (Malvern), equipped with a standard laser (10 mW, 633 nm).
This technique measures the diffusion of particles moving under
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Brownian motion and converts this to size and a size distribution
using the Stokes–Einstein relationship. For measuring antibody
formulation aggregates, 1 ml of 50 lg/ml polyclonal goat anti-mouse
IGF2R diluted in 0.1-lm-filtered PBS1X was loaded into polystyrene
cuvette. 0.1-lm-filtered 1 × PBS was used as control. Three measure-
ments of each sample were performed, and the mean was obtained.
NTA technique was performed with NanoSight NS300 (Malvern
Instruments Limited, Worcestershire, UK). NTA measurement
settings were set as follows: viscosity 0.91  0.03 cP, temperature
23.75  0.5°C, measurement time of 30 s for each of the five repeated
records per sample, infusion flow speed 30 and camera level 14.
Detection of anti-IGF2R antibody into injected muscles
after treatment
In order to detect the presence of anti-IGF2R, we performed WB
analysis of TAs and VMs of mdx mice injected for 4 and 9 weeks
with low- and high-dose antibody. Muscles from n.i. mdx and C57Bl
mice were used as controls. WBs analysis was performed as already
described, with minimal modifications. Briefly, muscles were
homogenized with an electric homogenizer in RIPA buffer supple-
mented with complete protease inhibitor cocktail and centrifuged to
collect the supernatants. Protein extracts were separated on poly-
acrylamide gels and transferred to nitrocellulose membranes. After
blocking, the membranes were incubated with HRP-conjugated
rabbit anti-goat secondary antibodies (DakoCytomation, USA) and
developed by ECL. Bands were visualized using Odyssey Infrared
Imaging System.
Statistical analysis
Values are expressed as the mean  SD or SEM. In our case of 3
treatment groups (1: control; 2: low dose of antibody; and 3: high
dose of antibody) with 10 animals per group, we used the Excel
function = Rand() to generate a column of random numbers in
column A and consequently in columns B and C. Blinding was
maintained during and after the intervention, and the responsible of
the experiments did not reveal the allocation sequence to the people
that conducted the experiments until the data were analysed. Statis-
tical comparisons among three or more groups were conducted
using one- and two-way ANOVA followed by Bonferroni’s multiple
comparison test to determine significance (*P < 0.05, **P < 0.01,
***P < 0.001; ****P < 0.0001). Exact P-values can be found in
Appendix Table S2. Otherwise, Student’s t-test was applied.
Expanded View for this article is available online.
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